JP2019535306A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535306A5
JP2019535306A5 JP2019542804A JP2019542804A JP2019535306A5 JP 2019535306 A5 JP2019535306 A5 JP 2019535306A5 JP 2019542804 A JP2019542804 A JP 2019542804A JP 2019542804 A JP2019542804 A JP 2019542804A JP 2019535306 A5 JP2019535306 A5 JP 2019535306A5
Authority
JP
Japan
Prior art keywords
seq
antigen
monoclonal antibody
binding fragment
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019542804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535306A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/077261 external-priority patent/WO2018077926A1/en
Publication of JP2019535306A publication Critical patent/JP2019535306A/ja
Publication of JP2019535306A5 publication Critical patent/JP2019535306A5/ja
Pending legal-status Critical Current

Links

JP2019542804A 2016-10-25 2017-10-25 Cd160膜貫通型アイソフォームと結合するモノクローナル抗体 Pending JP2019535306A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306392.8 2016-10-25
EP16306392 2016-10-25
PCT/EP2017/077261 WO2018077926A1 (en) 2016-10-25 2017-10-25 Monoclonal antibodies binding to the cd160 transmembrane isoform

Publications (2)

Publication Number Publication Date
JP2019535306A JP2019535306A (ja) 2019-12-12
JP2019535306A5 true JP2019535306A5 (cg-RX-API-DMAC7.html) 2020-12-03

Family

ID=57570549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542804A Pending JP2019535306A (ja) 2016-10-25 2017-10-25 Cd160膜貫通型アイソフォームと結合するモノクローナル抗体

Country Status (9)

Country Link
US (1) US11186635B2 (cg-RX-API-DMAC7.html)
EP (1) EP3532502A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019535306A (cg-RX-API-DMAC7.html)
KR (1) KR20190084264A (cg-RX-API-DMAC7.html)
CN (1) CN110121508A (cg-RX-API-DMAC7.html)
AU (1) AU2017351764A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019008345A8 (cg-RX-API-DMAC7.html)
CA (1) CA3080270A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018077926A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230071889A1 (en) 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
EP3812008A1 (en) * 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ose免疫治療公司 包含il-7變體之雙官能分子
GB202103706D0 (en) * 2021-03-17 2021-04-28 Ucl Business Ltd CD160 binding domain
JP2024515263A (ja) 2021-04-09 2024-04-08 オーエスイー・イミュノセラピューティクス 改善された特性を有する二機能性分子のための新規足場構造
US20240182572A1 (en) 2021-04-09 2024-06-06 Ose Immunotherapeutics Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
JP2025508086A (ja) * 2022-03-09 2025-03-21 オルデラン バイオテクノロジー 抗cd160膜貫通型アイソフォーム抗体
CN119907811A (zh) 2022-08-02 2025-04-29 Ose免疫疗法公司 针对cd28的多功能分子

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0689601B1 (en) 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
ATE386802T1 (de) 1997-06-12 2008-03-15 Novartis Int Pharm Ltd Künstliche antikörperpolypeptide
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
EP1522590B1 (en) 2000-06-28 2009-08-26 Glycofi, Inc. Methods for producing modified glycoproteins
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1725586B1 (en) 2004-03-02 2015-01-14 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
EP1626059A1 (en) 2004-08-09 2006-02-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
EP1898529A1 (en) 2005-06-28 2008-03-12 Pioneer Corporation Broadcast receiving apparatus, interference detecting apparatus and interference detecting method
PT3248613T (pt) 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
EP1880729A1 (en) 2006-07-20 2008-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of soluble CD160 to suppress immunity
NZ577085A (en) * 2006-11-15 2012-06-29 Medarex Inc Human monoclonal antibodies to btla and methods of use
EP2006299A1 (en) 2007-06-18 2008-12-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Identification of new isoforms of the MHC-class I specific receptor CD160 and uses thereof
EP2210903A1 (en) * 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
EP2548030B1 (en) * 2010-03-18 2015-05-27 Cornell University Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates
KR101847572B1 (ko) * 2010-05-28 2018-05-24 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 신혈관신생에 기초한 안 질환 치료용 항-cd160 특이적 항체
EP2635310A2 (en) 2010-11-05 2013-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013072714A1 (en) * 2011-11-15 2013-05-23 Centre National De La Recherche Scientifique (Cnrs) Antibodies for molecular imaging of vulnerable plaques in atherosclerosis
EP3245228A1 (en) 2015-01-16 2017-11-22 INSERM - Institut National de la Santé et de la Recherche Médicale Human monoclonal antibodies against orexin receptor type 1

Similar Documents

Publication Publication Date Title
JP2019535306A5 (cg-RX-API-DMAC7.html)
JP7345578B2 (ja) 新規抗pd-l1抗体
TWI853077B (zh) 新型抗cd39抗體
CN114007699B (zh) 拮抗剂抗cd7抗体
CN109535257B (zh) 新型双特异性cd3/cd19多肽复合物
JP2017504577A5 (cg-RX-API-DMAC7.html)
JP2016527314A5 (cg-RX-API-DMAC7.html)
JP2018519296A5 (cg-RX-API-DMAC7.html)
JP2014039548A5 (cg-RX-API-DMAC7.html)
JP2018508214A5 (cg-RX-API-DMAC7.html)
CA3044684A1 (en) Anti-sirp-alpha antibodies and methods of use thereof
JP2016531100A5 (cg-RX-API-DMAC7.html)
JP2020503891A5 (cg-RX-API-DMAC7.html)
JP2015535691A5 (cg-RX-API-DMAC7.html)
JP2016512551A5 (cg-RX-API-DMAC7.html)
JP2017504578A5 (cg-RX-API-DMAC7.html)
JP2018520667A5 (cg-RX-API-DMAC7.html)
JP2018524326A5 (cg-RX-API-DMAC7.html)
JP2015533853A5 (cg-RX-API-DMAC7.html)
JP2014523408A5 (cg-RX-API-DMAC7.html)
JP2016505556A5 (cg-RX-API-DMAC7.html)
CN114761429B (zh) 新型抗cd3/抗egfr双特异性抗体及其用途
CN115093481A (zh) 新型双特异性cd3/cd20多肽复合物
JP2017537082A5 (cg-RX-API-DMAC7.html)
CA3117864A1 (en) Novel antagonistic anti tnfr2 antibody molecules